Automotive Industry Grapples with Design Patent Obviousness: The Rosen-Durling Test Debated

The issue of design patent obviousness in the automotive industry has come under the spotlight recent times, particularly with the legal battle between LKQ Corp. and GM Global Technology Operations LLC. The case has reenergized discussions around the complex and often nebulous aspect of patent law. The central focus of the contention is the Rosen-Durling…

Read More

Navigating the Regulatory Climate: Holland & Knight’s Insightful Health Dose Bulletins

The American law firm, Holland & Knight, has published another of its insightful bulletins known as the ‘Health Dose’ on September 19, 2023. The regularly scheduled publications serve to update stakeholders—from health system leaders to policy makers—on developments and changes in legislative and regulatory terms that have a significant bearing on the health sector. This…

Read More

Design Patent Precedent Revisited: Federal Appeals Circuit Sheds Light on Intellectual Property Disputes

The latest case report from the Federal Appeals Circuit, concerning Columbia Sportswear North America, Inc. v. Seirus Innovative Accessories, Inc., (Appeal Nos. 2021-2299, -2338) provides an illuminating analysis of precedent concerning design patents and infringement scope. Dated September 15, 2023, this decade-old case offers fresh insight into the domain of intellectual property law, particularly in…

Read More

Federal Circuit Panel Clarifies Design Patent Infringement Analysis, Impacting Intellectual Property Law

Design patents play a distinct role in intellectual property law, often winding up in disputes between competitors. These cases can frequently escalate all the way to the Federal Circuit for review, if settlements are not reached. A prime example of this is last week’s significant decision in Columbia v. Seirus, which stirred prominent discussions in…

Read More

Court Upholds Genomics Patents, Bolstering Intellectual Property Rights in Innovation-Driven Industries

In a significant development in the sphere of genomics legal cases on September 14, 2023, the U.S. District Court for the District of Delaware vetoed Parse Biosciences Inc.’s (Parse) attempt to dismiss a complaint lodged by 10x Genomics Inc. (10x) and the Board of Trustees of Leland Stanford Junior University (Stanford). Parse was accused of…

Read More

Trump’s Legal Troubles Intensify Amid Constitution Misinterpretation and Admissions

In recent developments in the ongoing legal saga concerning the former US President Donald Trump, he seemingly confessed his involvement in a case currently under investigation. This full-throated admission has left his counsel in a difficult position. More details can be found here. His understanding and interpretation of the Constitution has also been called into…

Read More

FTC Crackdown on Improper Orange Book Patent Listings to Bolster Generic Drug Competition

In an announcement dated September 14, 2023, the Federal Trade Commission (FTC) issued a policy statement warning pharmaceutical companies against improper listings of patents in the FDA’s Orange Book. This is a remarkable move in the commission’s push to bolster generic competition and comes amid an era of rising scrutiny on practices perceived to thwart…

Read More

PTAB Denies T-Mobile’s Joinder Motions: An Intricate Legal Strategy with Broad Implications

In February of 2023, T-Mobile USA, Inc. (“T-Mobile”) submitted applications for four inter partes reviews (“the T-Mobile IPRs”) in a particularly complex legal maneuver. Specifically, these entailed two challenges of U.S. Patent No. 8,630,234 and two against U.S. Patent No. 10,880,721 electing to file with joinder motions. This development is noteworthy because, previously in June…

Read More

Reevaluating Patent Eligibility: The Impact of American Axle v. Neapco on Intellectual Property Law

In a recent case closely followed by intellectual property attorneys, the District of Delaware reexamined the remaining dispute claims in American Axle v. Neapco, following an appeal and petition for certiorari to the Supreme Court. At stake was whether the disputed claims were invalid due to the lack of patent-eligible subject matter. Described in more…

Read More

Navigating Patent Law Complexities: Wireless Charging for Implanted Medical Devices Case Sparks Change

In recent years, the Federal Circuit has faced novel challenges in understanding and interpreting patent laws. An interesting situation has risen from a decision of a case involving wireless charging through skin for implanted medical devices. According to JDSupra’s depiction of the case, the Federal Circuit highlighted the Patent Trial and Appeal Board’s (PTAB) adoption…

Read More

Navigating AI in Mergers and Acquisitions: 10 Key Considerations for Success

Artificial Intelligence (AI) continues to make significant strides across various sectors, and mergers and acquisitions (M&A) are no exception. As AI permeates more business models, it’s inevitably becoming a central component in M&A considerations. Primarily, the boom in AI systems and products, especially generative AI, has fuelled the surge in interest towards investing in, and…

Read More

Pharmaceutical Patent Dispute: Amgen Inc. v. Sandoz Inc. and the Future of Intellectual Property Law

In the case of Amgen Inc. v. Sandoz Inc., the dispute centres around Otezla® (Apremilast), a formulation extensively used in pharmaceutical industry. Defined within case numbers 2022-1147, 2022-1149, 2022-1150, 2022-1151, and 2023 WL 2994166 (Fed. Cir. Apr. 19, 2023), the proceedings are overseen by Circuit Judges Lourie, Cunningham, and Stark with Justice Lourie giving the…

Read More